Verismo Therapeutics Revenue and Competitors

Location

#2847

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Verismo Therapeutics's estimated annual revenue is currently $2.4M per year.(i)
  • Verismo Therapeutics's estimated revenue per employee is $85,804
  • Verismo Therapeutics's total funding is $50M.

Employee Data

  • Verismo Therapeutics has 28 Employees.(i)
  • Verismo Therapeutics grew their employee count by 27% last year.

Verismo Therapeutics's People

NameTitleEmail/Phone
1
CEO / co-founderReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
3
Quality Lead/ Chief StaffReveal Email/Phone
4
VP Clinical OperationsReveal Email/Phone
5
VP, Clinical OperationsReveal Email/Phone
6
Head Quality and ComplianceReveal Email/Phone
7
Director, MSATReveal Email/Phone
8
Director Corporate Development / Start-Up MemberReveal Email/Phone
9
Senior Director, Translational ScienceReveal Email/Phone
10
Senior Manager, Program ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M7-12%N/AN/A
#2
$4M3881%N/AN/A
#3
N/A7627%N/AN/A
#4
$0.9M50%N/AN/A
#5
$1.1M833%N/AN/A
#6
$10.9M617%N/AN/A
#7
$0.7M929%N/AN/A
#8
$4M20-5%N/AN/A
#9
$1.7M1122%N/AN/A
#10
$7.6M492%N/AN/A
Add Company

What Is Verismo Therapeutics?

Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.

keywords:N/A

$50M

Total Funding

28

Number of Employees

$2.4M

Revenue (est)

27%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.7M28N/AN/A
#2
$7.5M284%N/A
#3
$2.8M28-10%N/A
#4
N/A2840%N/A
#5
$4.9M28-15%N/A